EPI Übernahme - Wir halten zusammen
Die Krebsdiagnose Tests sollten doch in jedem Fall alles Wert sein und den Kurs Phantasien auslösen. m.M.
Optionen
| Boardmail an "Marty McFly" |
Wertpapier: Epigenomics AG |
Gestern hat Epi auf Facebook seine Emailadresse von .de auf .com umgestellt.
Man treibt die Amerikanisierung also zügig voran.
Das sind circa so viele wie in den letzten drei Monaten zusammen.
https://www.ariva.de/epigenomics-aktie/...n_bezug=1&clean_bezug=0
Optionen
| Boardmail an "tancho" |
Wertpapier: Epigenomics AG |
Lt. der Meldung wäre ab 2019 Herr Taapken wohl nicht mehr Finanzchef bei Medigene. Wie wäre es dann bei Epi, machs noch einmal richtig, Sie waren ja schon mal hier.
https://www.genengnews.com/gen-exclusives/...genetic-markers/77901138
A cfDNA Success—FDA-approved Colorectal Cancer Screening Test
Click Image To Enlarge +
Blood tests may one day provide for routine early screening for the presence of cancer. [NIH]
One area where cfDNA has been implemented clinically is in colorectal cancer, the second-leading cause of cancer death in the United States. Epi proColon (made by Epigenomics,) the only FDA-approved blood-based cfDNA test for screening, is based on the detection of tumor-specific methylation on the SEPT9 gene (septin-9 protein). In the DNA of colorectal cancer tissue, but not normal tissue, the cytosine residues on the SEPT9 gene are methylated. This cancer specific methylation can be harnessed to detect the presence of tumor cells in the colon.
Theo deVos, Ph.D., the director of development and commercial operations at Epigenomics, notes that the company is tackling multiple different cfDNA-based projects, in addition to advancing earlier detection of colorectal cancer. Another goal is to develop tools to be used in conjunction with other cancer screenings that may give inconclusive findings, such as CAT Scans for lung cancer. deVos’s goal is to “add information to make these findings more relevant without having to go in to do a biopsy.” The researchers at Epigenomics are also identifying new methylation biomarkers the company can add to cancer screening panels.
With regard to the power of using methylation for cancer screening, deVos says the choice of DNA sequence versus DNA methylation “strongly depends on what you are trying to do.” He notes, “if the clinical application is treatment selection, genetics are important because a lot of cancer treatments are designed around mutations.”
However, he adds that “for broader applications like screening, methylation allows us to find a biomarker that covers a whole range of cancers.” One example of the crossover of SEPT9 between cancers was detailed in a paper published in April, 2018 in EBioMedicine, by Oussalah et al. In this research, Oussalah and team used SEPT9 to identify hepatocellular carcinoma (HCC) in patients with cirrhosis.
In the field of cfDNA cancer screening, many eyes are focused on Illumina spinout Grail, due to their deep pockets and scientific bandwidth. Grail is striving to become the leader in the liquid biopsy field, as evidenced by the enormous undertaking of their ongoing Circulating Cell-free Genome Atlas (CCGA) Study. This project is designed to establish a baseline of cell free nucleic acid (cfNA) profiles in an estimated 15,000 people to be recruited by the end of 2018, including both cancer patients and healthy controls. To date, 11,000 people have enrolled.
This approach of gathering large amounts of data is an important one, according to Hao Wu Ph.D., an associate professor at the Department of Biostatistics and Bioinformatics at Emory University. “A major challenge right now is to collect more data, especially from large-scale, population level studies,” Wu says. “We should also collect data from normal people with different demographics, so that we can establish a baseline.”
In the initial discovery phase of CCGA, Grail took a three-pronged approach to gathering information about blood-based tests as a screening tool for early detection. The first looked at DNA mutations (single nucleotide variants and small insertions and/or deletions), the second used whole genome sequencing to detect abnormal number of copies of genes, and the third used bisulfite sequencing to analyze cfDNA methylation patterns.
Charlotte Arnold, head of communications at Grail, notes that “We are now optimizing our assays and machine learning algorithms to determine the most informative genomic features for continued development and validation of a blood test for early detection of multiple cancer types.”
Although Grail did not need more clout in the field, it gained some when it merged with Cirina in 2017, the company started by one of the founders of the cfDNA field, Dennis Lo, M.D., Ph.D. Lo pioneered the field of cfDNA through the discovery of cell-free fetal DNA circulating in maternal blood, work that deVos cites as, “the basis of some of the best work in the whole field.”
The Process is Easy, If You Have the DNA
The methylation pattern on cfDNA can be determined using bisulfite treatment which is easy, quick, and cheap. Bisulfite conversion kits can be purchased from many different vendors for a few hundred dollars for dozens of reactions.
Treating DNA with bisulfite changes cytosines (one of the four nucleotide DNA bases) into uracils, which are normally found in RNA. However, the change only happens in unmethylated cytosines. The cytosines that have methyl groups attached to them (5-methylcytosine), will not be converted to uracil. After bisulfite treatment, the DNA is sequenced. In the sequence, the methylated cytosines which were protected from conversion will still be read as a “C” whereas the unmethylated cytosines will have been changed. Therefore, because the bisulfite treatment creates methylation dependent changes in the DNA sequence, that analysis of the sequence after the bisulfite treatment reveals the methylation patterns on that piece of DNA.
With the kits available, bisulfite treatment of DNA seems as easy as any standard molecular biology protocol. However, many researchers in the field agree that the biggest challenge to working with cfDNA is getting enough of it. Not only is cfDNA found in extremely low concentrations, but it is also fragmented—and the bisulfite sequencing process fragments it further. Therefore, cfDNA can be difficult to obtain in adequate quantities.
It is a problem that is not easily solved. Increasing the signal seems a likely solution, but is not a panacea. When screening, deVos says “you want to have as high a sensitivity as possible at as high a specificity as possible. But, when you push the sensitivity up, things come up in the background.” The addition of more markers is one way to improve the process. However, technical advances in this process would improve cancer screening dramatically.
A second challenge, noted by Warton, is the ability to obtain blood that has been biobanked appropriately in order to use it clinically. Some of the cfDNA tests (like the FDA-approved Epi proColon) can use plasma, while others require cfDNA from serum. Although frequently mistaken for each other, serum and plasma cannot be used interchangeably. Serum contains more DNA than plasma, but the DNA is a contaminant from lysed leukocytes in the blood—another issue holding back clinical implementation that will require further technical development.
A Blood Test for Cancer Screening Is in the Future
Despite the work that needs to be done, Warton remains optimistic that there will be a day in the future when a routine screening blood test will identify both the presence of cancer and its location. And, she thinks that it may not be that far away. She says that any doubts can be dismissed by looking at how cfDNA has revolutionized prenatal testing. “The speed at which that work moved into the clinic happened at a breathtaking pace,” she says. “If cancer diagnosis were to follow down the same path, it will happen quickly.”
A recent development by Epigenomics is a step in the right direction. The company has designed a product to allow researchers to bring a plasma sample to bisulfite-?labeled DNA with one kit. With this, researchers and clinicians can run next generation sequencing (NGS) panels in their own laboratories, bringing the power of using cfDNA for cancer screening to anyone who wants to use it.
David Bull, the director of marketing at Epigenomics, wants to see a day when everyone is screened for colon cancer. Because, as he says, “screening tools are only useful if they are used.” He notes that “guaiac fecal occult blood test (gFOBT) is not a great test, but, studies have proven that when used annually this imperfect screening test reduces colon cancer mortality and morbidity.” Bull says that we have to look at these tests from a program standpoint—not a point in time. But at this point in time, the cfDNA field is at the beginning of a turning point that may end with a routine blood test at annual check-ups to screen for cancer.
A recent development by Epigenomics is a step in the right direction. The company has designed a product to allow researchers to bring a plasma sample to bisulfite-?labeled DNA with one kit. With this, researchers and clinicians can run next generation sequencing (NGS) panels in their own laboratories, bringing the power of using cfDNA for cancer screening to anyone who wants to use it.
übersetzt mit google
Eine aktuelle Entwicklung von Epigenomics ist ein Schritt in die richtige Richtung. Das Unternehmen hat ein Produkt entwickelt, mit dem Forscher eine Plasmaprobe mit einem Kit zu Bisulfit-markierter DNA bringen können. Damit können Forscher und Kliniker Next-Generation-Sequencing (NGS) -Panels in ihren eigenen Labors betreiben und damit die Möglichkeit nutzen, cfDNA für die Krebsvorsorge zu nutzen.
1. Angaben zu den Personen, die Führungsaufgaben wahrnehmen, sowie zu den in enger Beziehung zu ihnen stehenden Personen
a) Name
Name und Rechtsform: Armin M. Kessler and Ann C. Kessler Family Trust
2. Grund der Meldung
a) Position / Status
Person steht in enger Beziehung zu:
Titel:
Vorname: Ann Clare
Nachname(n): Kessler
Position: Aufsichtsrat
b) Erstmeldung
3. Angaben zum Emittenten, zum Teilnehmer am Markt für Emissionszertifikate, zur Versteigerungsplattform, zum Versteigerer oder zur Auktionsaufsicht
a) Name
Epigenomics AG
b) LEI
549300X1C4U862NDLN97
4. Angaben zum Geschäft/zu den Geschäften
a) Beschreibung des Finanzinstruments, Art des Instruments, Kennung
Art: Aktie
Beschreibung: Epigenomics American Depositary Receipt (unter Sponsored Level 1 Epigenomics-ADR Program) ISIN US29428N1028
b) Art des Geschäfts
Kauf
c) Preis(e) und Volumen
Preis(e) Volumen
18,17 USD 1817,00 USD
18,17 USD 1817,00 USD
18,17 USD 1817,00 USD
18,17 USD 34541,17 USD
d) Aggregierte Informationen
Preis Aggregiertes Volumen
18,17 USD 39992,17 USD
e) Datum des Geschäfts
2018-06-11; UTC−4
f) Ort des Geschäfts
Name: OTCQX MARKETPLACE
MIC: OTCQ
10.09.2018 Die DGAP Distributionsservices umfassen gesetzliche Meldepflichten, Corporate News/Finanznachrichten und Pressemitteilungen.
Medienarchiv unter http://www.dgap.de
Sprache: Deutsch
Unternehmen: Epigenomics AG
§Geneststraße 5
§10829 Berlin
Deutschland§
Internet: www.epigenomics.com
Optionen
| Boardmail an "HAL2016" |
Wertpapier: Epigenomics AG |
12,720 USD +0,01 +0,08% 13.08.2018, 15:30:04 Handelsplatz geschlossen: Nasdaq OTC
warum bezahlen Armin M. Kessler and Ann C. Kessler Family Trust jetzt 18,17 USD ?
kann mir das mal jemand erklären ?
Wandlung der am 2018-06-11 erworbenen 2.201 Epigenomics American Depositary Receipts (unter dem Sponsored Level 1 Epigenomics-ADR Program) mit einem aggregierten Volumen von 39.992,17 USD und einem Verhältnis von fünf Stammaktien zu einem Epigenomics American Depositary Receipt in 11.005 Stammaktien der Epigenomics AG
Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.
1. Angaben zu den Personen, die Führungsaufgaben wahrnehmen, sowie zu den in enger Beziehung zu ihnen stehenden Personen
a) Name
Name und Rechtsform: Armin M. Kessler and Ann C. Kessler Family Trust
2. Grund der Meldung
a) Position / Status
Person steht in enger Beziehung zu:
Titel: §
Vorname:§Ann Clare
Nachname(n): Kessler
Position: Aufsichtsrat
§
b) Erstmeldung
3. Angaben zum Emittenten, zum Teilnehmer am Markt für Emissionszertifikate, zur Versteigerungsplattform, zum Versteigerer oder zur Auktionsaufsicht
a) Name
Epigenomics AG
b) LEI
549300X1C4U862NDLN97
4. Angaben zum Geschäft/zu den Geschäften
a) Beschreibung des Finanzinstruments, Art des Instruments, Kennung
Art: Aktie §
Beschreibung:§Aktie ISIN DE000A11QW50 Epigenomics American Depositary Receipt (unter Sponsored Level 1 Epigenomics-ADR Program) ISIN US29428N1028
b) Art des Geschäfts
Wandlung der am 2018-06-11 erworbenen 2.201 Epigenomics American Depositary Receipts (unter dem Sponsored Level 1 Epigenomics-ADR Program) mit einem aggregierten Volumen von 39.992,17 USD und einem Verhältnis von fünf Stammaktien zu einem Epigenomics American Depositary Receipt in 11.005 Stammaktien der Epigenomics AG
c) Preis(e) und Volumen
Preis(e) Volumen§
18,17 USD 39992,17 USD
d) Aggregierte Informationen
Preis§Aggregiertes Volumen
18,17 USD 39992,17 USD
e) Datum des Geschäfts
2018-06-14; UTC−4
f) Ort des Geschäfts
Außerhalb eines Handelsplatzes
Wandlung der am 2018-06-11 erworbenen 2.201 Epigenomics American
Depositary Receipts (unter dem Sponsored Level 1 Epigenomics-ADR
Program) mit einem aggregierten Volumen von 39.992,17 USD und einem
Verhältnis von fünf Stammaktien zu einem Epigenomics American
Depositary Receipt in 11.005 Stammaktien der Epigenomics AG
Wandlung der ADR in Aktion...jetzt hab ich ein paar ???????... die sind in den USA doch gar nicht handelbar und nicht „haltbar“ im Depot...meiner bescheidenen Meinung nach.
Durch den Währungseffekt ein gutes Geschäft
Gilt eigentlich für die ADRs die Veröffentlichungspflicht nicht? 3 Monate ist ja schon sportlich...
Optionen
| Boardmail an "Marty McFly" |
Wertpapier: Epigenomics AG |
Quelle soll ep i Procolon auf Facebook sein
Bin da leider nicht
die beiträge nr. 39.968 und 69 von heute.
da wird ein bericht von goetzpartners research veröffentlicht.
goetzpartners ist ja nicht gerade kreisliga. ein kursziel von knapp unter 7 euro genannt.
aus dem bericht " epiprocolon wir derzeit in die medizinischen leitlinien der usa aufgenommen ".
habe ich was verschlafen ?
was sagen unsere experten im forum ????